STAT+: Longevity startup Retro Biosciences says latest fundraising values it at $1.8 billion
Why this matters: health reporting relevant to everyday decisions and well-being.
Retro Biosciences, the longevity startup backed by Open AI CEO Sam Altman, has raised more money at a $1.8 billion valuation, it announced Friday.&#x A0; Retro has a big mission: Add 10 healthy years to the human lifespan. It is seeking to do that by using a variety of technologies, including in vivo gene therapies, cell replacement therapies, and other approaches to spur younger, healthier cells into aging tissues.&#x A0; The company is currently running its first clinical trial — testing a pill designed to enhance the body’s ability to better clear out protein aggregates in patients with Alzheimer’s disease. Retro CEO Joe Betts-LaCroix told the audience at STAT’s Breakthrough Summit West on Tuesday that the trial is going “super good” and that researchers haven’t seen any dose-limiting toxicities. He said he anticipates releasing some data from the trial around August. Continue to STAT+ to read the full story…